- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Gambia trial opens over children death who consumed Maiden Pharma cough syrup
Banjul: A trial opened Tuesday in The Gambia's capital Banjul over the deaths of small children who took a cough syrup made by the India-based Maiden Pharmaceuticals.
Justice Ebrima Jaiteh of the High Court in Banjul adjourned the proceedings until November 7 after finding that three state defendants who had failed to appear "lacked diligence".
Some 70 children aged 5 and under died in 2022 after taking the over-the-counter medicines, leading to a national outcry in the West African nation of about 2.5 million people.
Nineteen plaintiffs representing family members who were victims in July filed the suit, according to Salieu Taal, president of The Gambia Bar Association and one of the lawyers representing the plaintiffs.
The families are suing five defendants -- Maiden Pharmaceuticals, local distributor Atlantic Pharmaceuticals, the Medical Controls Agency (MCA), the Ministry of Health and Attorney General Dawda A. Jallow -- to demand they admit that the children were killed by consuming contaminated medicines.
They are also suing for an admission that the MCA failed in its statutory duty to regulate the quality and safety of medicines.
They are demanding 15 million Dalasis (about $230,000) per child in damages.
None of the five defendants were present on Tuesday.
The health ministry, MCA and attorney general requested a delay to the start of the trial, a motion the judge dimissed. He ordered the three to pay 10,000 Dalasis to the plaintiffs.
The trial had already been delayed in July after the attorney general and health ministry claimed they had not been served subpoenas with adequate time to familiarise themselves with the lawsuit.
Beginning in September last year, The Gambia ordered a recall of several cough and cold medications, as well as all products manufactured by the Indian laboratory Maiden Pharmaceuticals from which the adulterated syrups originated, after the deaths from kidney failure of at least 70 young children.
It subsequently banned all products from the Indian firm.
According to the World Health Organization (WHO), lab tests found "unacceptable amounts" of diethylene glycol and ethylene glycol, which are commonly used as antifreeze and can be fatal when ingested.
The toxic impact from these substances includes "acute kidney injury which may lead to death," the agency has said.
Read also: India seeks corrective action from cough syrup firm Marion Biotech linked to Uzbek deaths
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Next Story